|1.||Sikic, Branimir I: 4 articles (01/2015 - 03/2004)|
|2.||Larson, Richard A: 4 articles (09/2010 - 08/2002)|
|3.||Litchman, M: 4 articles (05/2001 - 03/2000)|
|4.||George, Stephen L: 3 articles (09/2010 - 08/2002)|
|5.||Bloomfield, Clara D: 3 articles (09/2010 - 08/2002)|
|6.||Powell, Bayard L: 3 articles (09/2010 - 08/2002)|
|7.||Kolitz, Jonathan E: 3 articles (09/2010 - 08/2002)|
|8.||van der Pol, Marjolein A: 3 articles (01/2007 - 02/2003)|
|9.||Broxterman, Henk J: 3 articles (01/2007 - 02/2003)|
|10.||Ossenkoppele, Gert J: 3 articles (10/2005 - 02/2003)|
12/01/1997 - "This efficacy of P388/ADR tumors treatment was dependent on PSC 833 because treatment with liposomal DOX alone provided significantly less antitumor activity. "
02/01/1996 - "In the present study, the potential of PSC 833 in reversing multidrug resistance was evaluated in various systemic treatment models with leukemic and solid-tumor-bearing mice. "
01/01/1995 - "The present study was focused on the effects of PSC 833 on the distribution and toxicity of Dx in non-tumor-bearing CDF1 male mice. "
08/15/1991 - "Since the MDR-P388 tumor cells used in our studies belong to a highly resistant variant, with a much higher degree of drug resistance than the one known to occur in cancer patients, SDZ PSC 833 appears to be a very promising chemosensitizer."
08/01/2005 - "Animals with drug-sensitive (MCF/WT) and drug-resistant (MCF7/AdrR) tumors were treated by PSC833 and by carrier vehicle 1 h before imaging, respectively. "
|2.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
09/01/2003 - "The present study was designed to evaluate whether the combined use of Syto16, the Pgp blocker PSC833, and 7-AAD allows simultaneous detection of all parameters, with emphasis on applications in acute myeloid leukemia (AML). "
03/15/2001 - "Combined treatment with infused PSC 833 and DNR is well tolerated and has activity in patients with poor risk acute myeloid leukemia. "
11/01/2004 - "A chemotherapy dose-escalation study was performed with PSC-833 in patients younger than 60 years with untreated acute myeloid leukemia. "
10/01/1997 - "The ultimate therapeutic benefit of MDR modulation with PSC 833 is currently being tested in phase III clinical trials in acute myeloid leukemias (AMLs) and multiple myeloma."
03/15/2001 - "Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia."
03/01/2000 - "These results suggest that the combination of PSC 833 with MIT could be a promising treatment in reversing PGP-mediated MDR in leukemia patients."
12/01/2002 - "In the present study exposure of the Pgp inhibitor, PSC 833 (1200 ng/ml), to Pgp expressing KG1a/200 human leukemia cells provoked cell cycle arrest and apoptosis in vitro. "
01/01/2001 - "PSC 833 induced apoptosis in the human T leukemia cell lines: Molt-4 and Jurkat. "
11/01/2000 - "Furthermore, PSC 833 alone induced apoptosis in parental drug-sensitive leukemia cells, but not in both multidrug-resistant sublines studied."
05/01/2000 - "For the seven patients with Pgp-positive leukemia, the mean ratio increased by 52%, from 545 on day 1 to 830 on day 2 (P<.05) when valspodar was given. "
|4.||Ovarian Neoplasms (Ovarian Cancer)
12/01/2003 - "PSC 833, ONYX-015 and ADP53) are currently being investigated for ovarian cancer patients. "
08/01/1998 - "PSC833: initial clinical results in refractory ovarian cancer patients."
07/29/1996 - "We found that MRK-16 potentiated the MDR reversal activity of PSC833, and of CsA, in MDR sublines of human myelocytic leukemia K562 and human ovarian cancer A2780 cells. "
01/01/2002 - "Clinical trials using first- and second-generation Pgp modulators did establish proof of principle that in some settings, clinical drug resistance could be overcome with the addition of a Pgp modulator-for example, clinical resistance to paclitaxel, a Pgp substrate, in women with ovarian cancer was shown to be overcome in approximately 20% with the addition of PSC 833, a highly effective Pgp modulator. "
06/15/2001 - "Although the regimen used in this trial produced renewed responses in patients with heavily pretreated, refractory ovarian cancer, the value of valspodar in reversing resistance mediated by P-glycoprotein remains to be determined."
|5.||Thyroid Neoplasms (Thyroid Cancer)
|1.||Etoposide (VP 16)
|3.||valspodar (PSC 833)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Induced Hyperthermia (Thermotherapy)
|5.||Combination Drug Therapy (Combination Chemotherapy)